Follow
Leo F. Buckley, PharmD
Leo F. Buckley, PharmD
Department of Pharmacy, Brigham and Women's Hospital
Verified email at bwh.harvard.edu
Title
Cited by
Cited by
Year
Anticoagulants: a review of the pharmacology, dosing, and complications
M Alquwaizani, L Buckley, C Adams, J Fanikos
Current emergency and hospital medicine reports 1, 83-97, 2013
2152013
Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial)
BW Van Tassell, J Canada, S Carbone, C Trankle, L Buckley, ...
Circulation: Heart Failure 10 (11), e004373, 2017
1852017
Effects of sodium‐glucose cotransporter 2 inhibitors on 24‐hour ambulatory blood pressure: a systematic review and meta‐analysis
WL Baker, LF Buckley, MS Kelly, JD Bucheit, ED Parod, R Brown, ...
Journal of the American Heart Association 6 (5), e005686, 2017
1842017
Restenosis, stent thrombosis, and bleeding complications: navigating between Scylla and Charybdis
J Torrado, L Buckley, A Durán, P Trujillo, S Toldo, J Valle Raleigh, ...
Journal of the American College of Cardiology 71 (15), 1676-1695, 2018
1792018
Interleukin‐1 blockade inhibits the acute inflammatory response in patients with ST‐segment–elevation myocardial infarction
A Abbate, CR Trankle, LF Buckley, MJ Lipinski, D Appleton, D Kadariya, ...
Journal of the American Heart Association 9 (5), e014941, 2020
1722020
Interleukin-1 blockade in cardiovascular diseases: a clinical update
LF Buckley, A Abbate
European heart journal 39 (22), 2063-2069, 2018
1662018
IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction: Results From DHART2
BW Van Tassell, CR Trankle, JM Canada, S Carbone, L Buckley, ...
Circulation: Heart Failure 11 (8), e005036, 2018
1462018
Interleukin-1 blockade in acute decompensated heart failure: a randomized, double-blinded, placebo-controlled pilot study
BW Van Tassell, NA Abouzaki, CO Erdle, S Carbone, CR Trankle, ...
Journal of cardiovascular pharmacology 67 (6), 544-551, 2016
1212016
Intensive versus standard blood pressure control in SPRINT-eligible participants of ACCORD-BP
LF Buckley, DL Dixon, GF Wohlford IV, DS Wijesinghe, WL Baker, ...
Diabetes Care 40 (12), 1733-1738, 2017
1192017
Interleukin‐1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D‐HART2)
BW Van Tassell, LF Buckley, S Carbone, CR Trankle, JM Canada, ...
Clinical cardiology 40 (9), 626-632, 2017
1142017
Intravenous diuretic therapy for the management of heart failure and volume overload in a multidisciplinary outpatient unit
LF Buckley, DM Carter, L Matta, JW Cheng, C Stevens, RM Belenkiy, ...
JACC: Heart Failure 4 (1), 1-8, 2016
1022016
Dietary fat, sugar consumption, and cardiorespiratory fitness in patients with heart failure with preserved ejection fraction
S Carbone, JM Canada, LF Buckley, CR Trankle, HE Billingsley, ...
Basic to Translational Science 2 (5), 513-525, 2017
982017
Targeting the NLRP3 inflammasome in cardiovascular diseases
S Toldo, E Mezzaroma, LF Buckley, N Potere, M Di Nisio, G Biondi-Zoccai, ...
Pharmacology & therapeutics 236, 108053, 2022
962022
Systolic blood pressure time in target range and cardiovascular outcomes in patients with hypertension
N Fatani, DL Dixon, BW Van Tassell, J Fanikos, LF Buckley
Journal of the American College of Cardiology 77 (10), 1290-1299, 2021
772021
Obesity Contributes to Exercise Intolerance in Heart Failure With Preserved Ejection Fraction
S Carbone, LF Buckley, CR Trankle, DL Dixon, R Buzzetti, R Arena, ...
Journal of the American College of Cardiology 68 (22), 2487-2488, 2016
572016
Interleukin-1 Blockade for the Treatment of Pericarditis
L Buckley, MM Viscusi, B Van Tassell, A Abbate
European Heart Journal-Cardiovascular Pharmacotherapy, 2017
552017
Role for anti-cytokine therapies in severe coronavirus disease 2019
LF Buckley, GF Wohlford, C Ting, A Alahmed, BW Van Tassell, A Abbate, ...
Critical care explorations 2 (8), e0178, 2020
542020
A review of PCSK9 inhibition and its effects beyond LDL receptors
DL Dixon, C Trankle, L Buckley, E Parod, S Carbone, BW Van Tassell, ...
Journal of clinical lipidology 10 (5), 1073-1080, 2016
532016
Vorapaxar: the current role and future directions of a novel protease-activated receptor antagonist for risk reduction in atherosclerotic disease
RJ Gryka, LF Buckley, SM Anderson
Drugs in R&D 17, 65-72, 2017
522017
Low NT‐proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction
LF Buckley, JM Canada, MG Del Buono, S Carbone, CR Trankle, ...
ESC heart failure 5 (2), 372-378, 2018
502018
The system can't perform the operation now. Try again later.
Articles 1–20